The Emerging Role of Cyclin-Dependent Kinases (CDKs) in Pancreatic Ductal Adenocarcinoma

被引：63
作者：
Garcia-Reyes, Balbina [1 ]
Kretz, Anna-Laura [1 ]
Ruff, Jan-Philipp [1 ]
von Karstedt, Silvia [2 ,3 ]
Hillenbrand, Andreas [1 ]
Knippschild, Uwe [1 ]
Henne-Bruns, Doris [1 ]
Lemke, Johannes [1 ]
机构：
[1] Ulm Univ Hosp, Dept Gen & Visceral Surg, Albert Einstein Allee 23, D-89081 Ulm, Germany
[2] Univ Hosp Cologne, Dept Translat Genom, Weyertal 115b, D-50931 Cologne, Germany
[3] Univ Cologne, Cologne Excellence Cluster Cellular Stress Respon, Joseph Stelzmann Str 26, D-50931 Cologne, Germany
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2018年 / 19卷 / 10期
关键词：
pancreatic cancer; pancreatic ductal adenocarcinoma; CDK; cyclin-dependent kinase; INHIBITOR DINACICLIB MK-7965; CHRONIC LYMPHOCYTIC-LEUKEMIA; TRAIL-INDUCED APOPTOSIS; I DOSE-ESCALATION; CELL-CYCLE; PROTEIN-KINASE; S-PHASE; DNA-DAMAGE; REPLICATION STRESS; ANTITUMOR-ACTIVITY;
D O I：
10.3390/ijms19103219
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
The family of cyclin-dependent kinases (CDKs) has critical functions in cell cycle regulation and controlling of transcriptional elongation. Moreover, dysregulated CDKs have been linked to cancer initiation and progression. Pharmacological CDK inhibition has recently emerged as a novel and promising approach in cancer therapy. This idea is of particular interest to combat pancreatic ductal adenocarcinoma (PDAC), a cancer entity with a dismal prognosis which is owed mainly to PDAC's resistance to conventional therapies. Here, we review the current knowledge of CDK biology, its role in cancer and the therapeutic potential to target CDKs as a novel treatment strategy for PDAC.
引用
收藏
页数：28
相关论文
共 249 条
[21]  
Besset V, 1999, CELL GROWTH DIFFER, V10, P173
[22]   Cyclin I activates Cdk5 and regulates expression of Bcl-2 and Bcl-XL in postmitotic mouse cells [J].
Brinkkoetter, Paul T. ;
Olivier, Paul ;
Wu, Jimmy S. ;
Henderson, Scott ;
Krofft, Ronald D. ;
Pippin, Jeffrey W. ;
Hockenbery, David ;
Roberts, James M. ;
Shankland, Stuart J. .
JOURNAL OF CLINICAL INVESTIGATION, 2009, 119 (10) :3089-3101
[23]   KRAS: feeding pancreatic cancer proliferation [J].
Bryant, Kirsten L. ;
Mancias, Joseph D. ;
Kimmelman, Alec C. ;
Der, Channing J. .
TRENDS IN BIOCHEMICAL SCIENCES, 2014, 39 (02) :91-100
[24]   Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas [J].
Bukholm, IRK ;
Bukholm, G ;
Nesland, JM .
INTERNATIONAL JOURNAL OF CANCER, 2001, 93 (02) :283-287
[25]   Cellular mechanisms of tumour suppression by the retinoblastoma gene [J].
Burkhart, Deborah L. ;
Sage, Julien .
NATURE REVIEWS CANCER, 2008, 8 (09) :671-682
[26]   Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial [J].
Burris, HA ;
Moore, MJ ;
Andersen, J ;
Green, MR ;
Rothenberg, ML ;
Madiano, MR ;
Cripps, MC ;
Portenoy, RK ;
Storniolo, AM ;
Tarassoff, P ;
Nelson, R ;
Dorr, FA ;
Stephens, CD ;
VanHoff, DD .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) :2403-2413
[27]   Driving the Cell Cycle Through Metabolism [J].
Cai, Ling ;
Tu, Benjamin P. .
ANNUAL REVIEW OF CELL AND DEVELOPMENTAL BIOLOGY, VOL 28, 2012, 28 :59-87
[28]   The fate of pancreatic tumor cell lines following p16 overexpression depends on the modulation of CDK2 activity [J].
Calbó, J ;
Serna, C ;
Garriga, J ;
Graña, X ;
Mazo, A .
CELL DEATH AND DIFFERENTIATION, 2004, 11 (10) :1055-1065
[29]   FREQUENT SOMATIC MUTATIONS AND HOMOZYGOUS DELETIONS OF THE P16 (MTS1) GENE IN PANCREATIC ADENOCARCINOMA [J].
CALDAS, C ;
HAHN, SA ;
DACOSTA, LT ;
REDSTON, MS ;
SCHUTTE, M ;
SEYMOUR, AB ;
WEINSTEIN, CL ;
HRUBAN, RH ;
YEO, CJ ;
KERN, SE .
NATURE GENETICS, 1994, 8 (01) :27-32
[30]   The multitalented Mediator complex [J].
Carlsten, Jonas O. P. ;
Zhu, Xuefeng ;
Gustafsson, Claes M. .
TRENDS IN BIOCHEMICAL SCIENCES, 2013, 38 (11) :531-537
12345678910